Background: Inhalation technique and medication adherence are highly important for the management of chronic obstructive pulmonary disease (COPD) since they are essential pre-requisites for achieving full therapeutic effect in patients. Community pharmacists are in the best position to deliver services in these two areas.
Introduction and background
Chronic Obstructive Pulmonary disease (COPD) is a chronic condition characterised by airflow limitation that is progressive in nature and partially reversible [1] . Tobacco smoking, indoor and outdoor pollution are all risk factors for COPD development [2] .
One of the main objectives of the Global Initiative for Chronic Obstructive Lung
Disease (GOLD) is to increase awareness of this condition [2] . This is particularly important due to the high economic and social burden of COPD on healthcare systems worldwide [1, 2] . In the European Union, the estimated cost of COPD to healthcare systems (as direct costs only) is 38.6 billion Euros (equivalent to $42.3 billion); whereas in USA this was found to account to a budget of $29.5 billion as direct costs and $20.4 billion as indirect costs [2] .
Inhalation technique (IT) and medication adherence (MA) are two key areas that should be looked upon with serious consideration when addressing management of COPD patients. IT is the process through which the patient correctly performs a number of steps in certain order to obtain the adequate dose out of the inhaler device [3] . The importance of IT stems from the fact that inhalation therapy represents the main pillar in COPD treatment [4] [5] [6] [7] [8] . It is the best treatment strategy to ensure delivery of adequate concentrations of the administered drug directly to the lungs [3] [4] [5] [9] [10] [11] . Adherence is defined as the degree by which a patient follows a mutually agreed plan including medication and life style changes [12] . According to the World Health Organisation (WHO), adherence to therapy in chronic conditions is estimated to be only 50% in developed countries and lower in developing countries [12] .
Incorrect IT may lead to poor disease control [6] . Some authors argue for poor IT to be a form of poor adherence [13] , whereas others see that poor adherence can be triggered by poor IT, as the latter can result in patient's dissatisfaction with the treatment [3] . This can lead to medication wastage due to prescribing higher doses or even additional medications thus increasing the financial burden of the disease on healthcare systems [7, 10] . In some studies, around 60% of COPD patients had poor adherence to their inhalation therapy [14, 15] . A recent review reported a wide variation in adherence rates for asthma and COPD patients ranging from 22% to 78% [16] . Regarding IT, evidence from Europe shows that up to 50% of patients fail to use their inhalers correctly [17] . Whereas, another review highlighted that nearly 100% of patients perform mistakes in their IT that consequently result in delivering an inadequate dose of the inhaled medication [18] . Poor adherence and suboptimal IT can lead to increased healthcare costs and poor health outcomes. Thus, there is a need for interventions to improve these two areas.
The aim of this paper is to provide a review of studies evaluating the impact of community pharmacists' interventions on COPD management focusing mainly on IT and MA.
Materials and Methods: Search Strategy
The search strategy included primary and secondary sources. The following databases were searched: Medline, Scopus, PubMed, Google scholar, Science direct. Key words used in the primary search were: community pharmacy, community pharmacists, inhaler technique, inhalation technique, COPD management, COPD, medication adherence, respiratory patients. The search was limited to articles written in English language and published in the period from January 2005 -February 2015. A manual search of reference lists of primary sources was done to identify any additional studies meeting the inclusion criteria.
Inclusion and exclusion criteria
The inclusion criteria for this review were: studies in English language and studies with interventions done by community pharmacists (CPs) on COPD patients focusing on IT and MA. Studies including COPD and asthma patients together, and observational studies involving CPs or those conducted in community pharmacy settings were also included. As the last decade has witnessed the implementation of community pharmacy medication management services, in many countries, that targets patients with LTCs [19] [20] [21] The excluded studies were as follow: three studies with interventions conducted by clinical/ hospital pharmacists on COPD patients, nine studies including both asthma and COPD patients where by the interventions were not done by CPs, two documents that constituted grey literature, one study in Dutch language, and one study with pharmacist-led intervention but focusing on COPD exacerbation management with systemic corticosteroids. A study with intervention done by CPs was excluded to avoid duplication of data since the data was once published jointly with asthma patients and once on COPD patients only. The study pertaining to COPD patients exclusively was included in the review. In addition, 69 studies that were conducted on asthma patients only either by CPs or other HCPs were excluded ( Figure 1 ).
Results
The search of primary sources identified nine articles that met the inclusion criteria; four studies involved COPD and asthma patients and five studies involved COPD patients only. Search of secondary sources identified one additional study including asthma and COPD patients which was included in the review. Thus ten studies were included in this review. Only one study had an intervention involving IT and MA, three studies focused on IT specifically, four studies had an intervention which partly focused on either IT and/or MA and two studies were non-interventional. The steps of the research process for the identification of relevant articles are provided in The summary of the studies reviewed in this paper is presented in Table 1. 6 | P a g e FIGURE 1. Selection of the relevant studies included in the review. Likewise, a 4.1% reduction in the percentage of smokers in the final sample (n=137) was observed which was not statistically significant (P= 0.219). As for QoL, the mean change in EQ-5D score was 0.029 between baseline and follow-up (for EQ-5D, 0.03 is regarded as the minimal important difference [22] ). The EQ-5D was used to estimate the QALY (quality-adjusted life year) change associated with the intervention. Change in QALY was calculated to be 0.008 (95% CI: 0.000 to 0.017) after a follow-up period of 201 days. The intervention was reported by the researchers to be cost-effective with a mean savings of £87.66 per patient for total NHS costs and £94.12 for total societal costs (i.e.: total NHS costs + cost of lost productivity). The mean cost-saving associated with the intervention was mainly due to the reduction in the use of NHS services notably hospital admissions. However, the results should be treated with some caution due to the before-and-after study design, the lack of a comparison control group (CG), and the fact that the intervention was conducted in winter period when COPD is expected to be worse in comparison to the pre-intervention period [23] .
In Netherlands, a large scale study reported that pharmacist-led interventions can improve sub-optimal medication treatment in COPD and asthma patients. The study that CPs are in the best position to deliver these services. Study limitations were related to its short duration and the possibility of selection bias. In addition, the authors had no information regarding any possible outside training on IT that might have been taken by the patients during the study period [5] .
In Belgium, the study of Mehuys et al. [9] was the first cross-sectional, observational study on COPD treatment to be conducted in the community pharmacy setting. The study was based in 93 pharmacies and involved 555 COPD patients. Data regarding COPD medication, smoking history and vaccination status were collected from participants by questionnaires. IT was assessed by checking against device specific checklists, whereas adherence was assessed by retrospective analysis of prescription refill rates for 12 months. Results showed that management of COPD patients in primary care is sub-optimal. Almost half (48%) of the patients had poor MA, 40% were smokers, 21% and 3.5% made errors in IT for rescue and control medications respectively, and only 65% of patients under 65 had flu vaccination. The researchers concluded that CPs can have a potential impact on improving COPD management by focusing more on the following four areas: smoking cessation, influenza vaccination, MA and IT and proposed this as a hypothesis for future testing.
Interestingly, the study of Tommelein et al. [25] evaluated the hypothesis stated above. It was the first randomised controlled trial (RCT) to address the impact of CPs' intervention on IT and MA as primary outcomes in COPD patients in Belgium.
This large-scale trial involved 734 COPD patients who were blinded with respect to group allocation. The trial lasted for three months; patients were followed up at one and three months across 170 community pharmacies. CPs received training about quickly and deeply through device) dropped from 15.6% at baseline to 1.2% after three months in the IG, whereas in the CG the drop was from 11.6% to 4.6% (P= 0.002). Another interesting result in this study was the significant likelihood to obtain a 100% inhalation score as a result of the intervention (odds ratio 3.03, 95%CI: 2.12-4.34; P <0.0001) in comparison to no intervention. Likewise, a significant likelihood to obtain more than 80% Medication refill adherence (MRA) scores in the IG in comparison to CG (odds ratio: 2.15, 95%CI: 1.46-3.14; P<0.0001). There was also a significant reduction in annual hospitalisation rate (P= 0.003) and decrease in the annual severe exacerbation rate (P < 0.007) in comparison to the CG. However, there was no significant improvement in health status (at three months, P values for CAT score and EQ-5D were 0.832 and 0.19 respectively) or smoking status (P= 0.33) which was attributed to the short study duration. Other limitations include selection bias since participation is more likely to involve motivated patients. Another source of bias would be that CPs in the study were both doing the educational intervention and measuring their own performance. Furthermore, MRA and IT scores were only calculated for the principal maintenance drug even if the patient is taking more than one inhaled medication [25] . The cost effectiveness analysis of this intervention in the Belgian Healthcare system showed a cost savings of €227 per patient (95%CI: €58-€403) in the IG for a one-year time period. Savings were mainly generated due to the reduction in exacerbation treatment expenses in the IG compared to CG. QALY gain was minimal in this study (<0.001 QALYs) which was attributed mainly to reduction in exacerbations [26] .
In Bulgaria, a RCT was done to assess the effect of educational intervention on QoL for COPD patients, forced expiratory volume in one second (FEV1) Patients in the CG were not provided with any information and received usual care (i.e.: routine dispensing services). Results showed that only improvement in FEV1 rate was statistically significant for IG compared to CG (after four months, p< 0.05).
There was improvement in QoL and IT within the IG itself between baseline and the end of the study, but this was not statistically significant when compared to the CG.
However, the researchers attributed these results to the short duration of the study.
They also highlighted that such results cannot be generalised in the country due to the small sample size [27] .
Impact of community pharmacists on the management of COPD: review of evidence from other developed countries
In other developed countries such as Canada, a small pilot study was conducted to Approximate time required to deliver this service was 30 minutes per patient and hence lack of time was identified by CPs as a potential barrier for service delivery [28] .
In New Zealand, a recent study assessed IT among 103 patients (86 with asthma and 17 with COPD) in 26 community pharmacies. Prior assessment, the researchers received training about the correct IT for all devices available in the country. Almost half (around 47%) of the assessments done indicated poor IT. The study also included a patient survey about previous IT education and re-assessment. Most of the patients (76%) received this education from the doctor, followed by 11% from a nurse, 9% from others (parents, internet, leaflets) and only 4% from the pharmacist.
As for technique re-assessment, 44% of patients had their IT rechecked with only 1% of them having this done by a pharmacist. This showed that the role of CPs was not prominent in IT education and re-assessment. Consequently, the authors emphasised the need to reinforce IT education and re-assessment through an interdisciplinary approach [4] .
In Australia, a study by Bosnic-Anticevich et al. [29] was the first one investigating the effect of two educational interventions regarding IT in community pharmacy setting. Reduction in the number of patients making errors in IT from 78.6% at baseline to 28.3% after the intervention (P < 0.001). Drop in average number of errors from 2.5 to 0.5/ patient (P < 0.001).
25% dropout among recruited CPs in the study due to lack of time, staff shortage, illness or difficulties in recruiting patients.
Mehuys et al (2010)[9]
Crosssectional observational study ( 
Discussion:
This review showed that CPs had a positive impact in relation to IT education and MA of COPD patients. Most of the studies reviewed involved educational interventions. With respect to IT, the offered interventions were found to significantly reduce IT errors or even improve the choice of the inhaler [5, 23-25, 28, 29] . For MA, the review showed that CPs interventions resulted in improving adherence to inhaled medications which was statistically significant in the addressed studies [8, 23, 25] . This is consistent with other studies which show that pharmacist-delivered interventions can lead to significant improvement in medications adherence in other diseases [30, 31] . Two studies [23, 25, 26] in this review showed that the provided interventions were cost-effective in terms of reducing hospitalisation rate and severe exacerbation rate. There was a cost saving of £94.12 per patient (equivalent to €133) for six months in Wright et al. [23] study in the UK and €227 per patient for one year in Tommelein et al. [25, 26] study in Belgium. This highlights that IT and MA interventions provided by CPs are not only beneficial for patients but also for the healthcare system.
As seen from this review, there are only a few studies addressing the impact of CPs in COPD management. Some case studies which involved CPs were found during the literature search but these were not published as primary literature and hence could not be used in this review. The scarcity of research in this area can have two possible explanations. First, COPD is still underdiagnosed in many countries [32] [33] [34] [35] [36] [37] [38] [39] [40] .
Estimates by the Department of Health in the UK indicate that approximately 2.2 million people are still undiagnosed [1] .This has been corroborated by a recent study, which showed that the chances of early diagnosis of COPD by doctors in the UK have been missed in 85% of cases in the five years before the actual diagnosis [41] . In the USA, 12.7 million people have COPD. However, evidence suggests that around 24 million have impaired lung function, indicating that almost half of the cases in the USA remain undiagnosed [42] . Second, the potential role of CPs in the reduction of medical and economical costs of inappropriate medication use is still not well recognised by the public. This can be partly attributed to the top down nature of the health sector; patients usually perceive doctors of higher authority in the medical hierarchy in comparison to pharmacists [43] . The call for enhancing the agenda for research into the impact of CPs on health has already been raised in the UK [43] . It can be argued that this approach should also be followed by other countries given the economic burden of COPD on healthcare systems all over the world.
Nevertheless, it is obvious from the studies reviewed in this paper that evidence regarding impact of CPs on COPD management is growing in the literature, since most of the studies reviewed were published between 2010 and 2015.
There was a clear emphasis from the reviewed studies on the need to provide patients with repeated instructions on correct IT by CPs and not to consider it as a one-time service in order to ensure sustainability [5, 8, 29] . The German study [5] in this review highlighted that patients benefited from IT education intervention irrespective of their previous education. On the other hand, two studies [4, 29] in this review showed how the role of CPs in IT education and re-assessment was not prominent. There are three possible reasons for this issue. The first reason might be the lack of sufficient knowledge and skills by CPs in IT education [44] [45] [46] . Several studies have shown that HCPs including pharmacists lack the knowledge needed to educate patients about correct IT [47] [48] [49] [50] [51] . The second reason could be that although
CPs might be aware of the importance of IT as a concept, yet they might not be fully aware of the importance of sustaining the correct IT in patients and the possibility of technique deterioration, even if patients have been using their inhalers for years.
Consequently, CPs overlook the necessity of IT assessment on a routine basis.
Thus, despite the obvious importance of inhalation therapy as a treatment strategy in respiratory conditions, the significance of correct IT gets overlooked [9] . The third reason is the lack of clarity within healthcare systems as to which professional has responsibility for IT assessment [4, 52] hence pharmacists do not feel accountable for it. In fact, previous studies emphasised that HCPs should not make assumptions that their patients are being instructed by other colleagues from different disciplines about IT and should assure routine education and re-checking of their patients' IT [52, 53] .
Existing evidence suggests that IT decline over time due to patients forgetting the proper instructions [17, 18, 29] . However, there was a disparity between the Japanese and the Australian study reviewed about the optimal frequency for IT rechecking and education. While the Japanese study recommended this to be done every six months as a minimum, the Australian study showed that a two-month gap period is sufficient to cause decline in IT even with patients using their inhalers for years. Interestingly, a previous study has shown the presence of a significant positive relationship between the provision of repeated IT instruction and adherence (p=0.04) and HRQoL (P=0.017) in COPD patients [54] . However, the frequency of repetition was not clearly specified [54] . COPD guidelines such as GOLD emphasise the importance of IT re-checking at each visit but with no specific frequency [2] . The National Institute for Health and Care Excellence (NICE) guidelines specify the frequency as once yearly [55] . Therefore, more research is needed to determine the optimal frequency of IT assessment and education to avoid deterioration of IT in patients.
Conclusions
This paper aimed at reviewing studies evaluating CPs' interventions and their impact on COPD management. As seen from this review, there is paucity of studies investigating such impact. The reviewed studies revealed that CPs can have a positive and cost-effective impact in the management of COPD in relation to MA and IT education which in turn can decrease medication wastage, hospital admissions and severe COPD exacerbations. However, the role of CPs is still not fully studied or recognised, thus there is a clear need for more research. The review also highlighted the need for more research to achieve a consensus on the frequency of IT rechecking and education to prevent technique deterioration. The results highlight the need for healthcare systems to recognise more the role of CPs in COPD management in two critical areas that are still challenging in real practice.
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